Results 31 to 40 of about 454 (136)
PF399 GENE EXPRESSION PROFILING OF CD26+ LEUKEMIC STEM CELL POPULATION FROM CML PATIENTS
HemaSphere, Volume 3, Issue S1, Page 151-152, June 2019., 2019 Background:
Nowadays, chronic myeloid leukemia (CML) has become a well manageable disease and majority of the patients achieve remission on tyrosine kinase inhibitor (TKI) treatment. However, the disease usually shows a low‐level persistence during therapy that arises from putative leukemic stem cells (LSC), which are, despite BCR‐ABL1 positivity ...D. Smitalová, M. Culen, Z. Herudkova, E. Budinska, J. Mayer, Z. Racil, M. Romzova +6 morewiley +1 more sourceApoptosis resistance in chronic myelogenous leukemia [PDF]
Einstein (São Paulo), 2005 The chronic myeloid leukemia (CML) is the three-phasemyeloproliferative disorder, dependent on the expression of theoncoprotein Bcr-Abl, which is the product of the reciprocaltranslocation between chromosomes 9 and 22, resulting in thePhiladelphia ...Fabíola Attié de Castro, Jacqueline de Fátima Jacysyn, Ana Elisa Bueno-da-Silva, Nelson Hamerschlak, Gustavo Pessini Amarante-Mendes +4 moredoaj PF401 IMMUNE SYSTEM AND CHRONIC MYELOID LEUKEMIA: THE IMPACT OF TYROSINE KINASE INHIBITORS
HemaSphere, Volume 3, Issue S1, Page 152-153, June 2019., 2019 Background:
During carcinogenesis, tumor cells alter their immunogenicity in an attempt to escape surveillance of the immune system (SI). This surveillance process involves NK cells and T lymphocytes, and various immunological factors, in order to combat tumor progression.R.S. Alves, S.E. McArdle, J. Vadakekolathu, A.C. Gonçalves, P. Freitas‐Tavares, A. Pereira, A.M. Almeida, A.B. Sarmento‐Ribeiro, S. Rutella +8 morewiley +1 more sourcePF402 PECULIARITIES OF THE EXPRESSION OF KI‐67 AND CD34 HEMOPOIETIC PRECURSOR CELLS IN PB AND BM OF CML PATIENTS WITH THE DIFFERENT RESPONSES TO IMATINIB AND NILOTINIB THERAPY
HemaSphere, Volume 3, Issue S1, Page 153, June 2019., 2019 Background:
The main feature of CML is the formation of the BCR‐ABL gene, the product of which has a pronounced tyrosine kinase activity, which is due to the suppressing effect of the protein regulators of proliferation and apoptosis. The result is an increase of the proliferation of tumor cells, the marker of which is the Ki‐67 protein.T. Perekhrestenko, I. Sviezhentseva, U. Melnyk, I. Dyagil +3 morewiley +1 more sourcePF403 NEGATIVE MR4.0 CHRONIC MYELOID LEUKEMIA AND ITS IMPLICATIONS FOR TREATMENT‐FREE REMISSION
HemaSphere, Volume 3, Issue S1, Page 153-154, June 2019., 2019 Background:
In the last few years, several clinical discontinuation trials have demonstrated that 40–60% of chronic phase CML patients (CP‐CML) who have achieved a stable deep molecular response, can stop therapy without relapsing. However, there is no consensus as to whether or not the depth of the molecular response is a prognostic factor for ...N. Cerveira, J. Diamond, S. Matos, M.L. Amorim, M. Coucelo, S. Bizarro, A.T. Simões, F. Pierdomenico, M. Lopes, L. Ribeiro, M. Carmo‐Fonseca, J.E. Guimarães, A. Almeida, M.R. Teixeira +13 morewiley +1 more sourceS881 PREGNANCY OUTCOME IN FEMALE PATIENTS WITH CHRONIC MYELOID LEUKEMIA WORLDWIDE: ANALYSIS OF 305 CASES OF THE EUROPEAN LEUKEMIA NET REGISTRY
HemaSphere, Volume 3, Issue S1, Page 395-396, June 2019., 2019 Background:
Family planning is important in patients (pts) with chronic myeloid leukemia (CML) who can have a near normal lifespan in tyrosine kinase inhibitors (TKI) era. Management of CML on conceptions and pregnancies is not defined as cases are rare and data are scarce.E. Chelysheva, A. Turkina, D. Rea, P. Rousselot, F.E. Nicolini, M.M. Trawinska, A. Romano, M. Malagola, D. Cangemi, I. Dyagil, K. Kotlyarchuk, K. Kazakbaeva, S. Saliev, C. Pavlovsky, B. Moiraghi, D.‐W. Kim, H. Klamova, M. Yassin, K. Meliktesyan, G. Mikhailov, P. Ganeva, S. Osorio, M. Mauro, E. Polushkina, R. Shmakov, J. Chabaeva, S. Kulikov, E. Abruzzese +27 morewiley +1 more sourceMutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response [PDF]
, 2012 The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK).Abdellatif, Abell, Abu-Baker, Alessi, Amati, Ambrosetti, Amzel, Anderson, Anderson, Andreeff, Arthur, Asselin, Atasoy, Auberger, Auberger, Avruch, Baccarini, Baccarini, Backer, Baker, Barata, Barford, Bartek, Barthorpe, Bartke, Basu, Batist, Berberich, Beretta, Bernards, Bernstein, Bhatia, Blagosklonny, Blagosklonny, Blagosklonny, Blagosklonny, Blagosklonny, Blagosklonny, Blagosklonny, Blagosklonny, Blagosklonny, Blagosklonny, Blagosklonny, Blenis, Blenis, Blenis, Bonavida, Bonilla, Bosenberg, Bouscary, Boyd, Brewer, Bristow, Brown, Buckhaults, Cammenga, Cantley, Cantley, Cantrell, Caro, Carr, Catling, Cervello, Chang, Chiang, Cho, Choudhury, Clevers, Cocco, Cochran, Coffer, Cohen, Cook, Cooks, Cordon-Cardo, Cordon-Cardo, Cosma, Costello, Couch, Crespo, Crespo, Crespo, D'Arcangelo, Dalla-Favera, Darzynkiewicz, de Magalhaes, de Magalhaes, Dean, Dennis, DePinho, Dobrovic, Downward, Du, Dulic, Egan, Egan, Eick, El-Deiry, Elledge, Emi, Engelman, Erneux, Erol, Felip, Ferrando, Finkel, Fisone, Fletcher-Sananikone, Flørenes, Font de Mora, Font de Mora, Foster, Frank, Fruhbeck, Furdui, Garcia de Herreros, Geliebter, Giaccia, Girard, Glynn, Goncharova, Goncharova, Gould, Graff, Gray, Greenberg, Gu, Guan, Gurtner, Gutmann, Habib, Halazonetis, Hall, Hall, Hall, Hall, Haramis, Hay, Hedley, Hemmings, Hemmings, Hengstschlager, Hengstschläger, Hewison, Heynck, Horii, Horwitz, Hotchin, Hoyland, Huang, Huang, Huang, Hung, Hunter, Hurst, Iozzo, Irving, Iwai, Jacinto, Jacinto, Jacinto, Janes, Jang, Jat, Jiang, Jiang, Joe, Johansson, Johnson, Jücker, Kallioniemi, Kazanietz, Kenney, Keyse, Khwaja, Kim, Kirby, Knudsen, Kolch, Kolch, Kolch, Kornblau, Kris, Kroemer, Kroemer, Kroemer, Kroemer, Kroemer, Kroemer, Krolewski, Krystal, Krystal, Kumar, Larsson, Lawler, Lawler, Lee, Lee, Lee, Lee, Lee, LeRoith, Li, Li, Liao, Libra, Libra, Lichtenstein, Lin, Lippincott-Schwartz, Lisanti, Lisanti, Lisanti, Lisanti, Lisanti, Liu, Longo, Lu, Lu, Maestro, Mak, Maki, Malliri, Man, Manning, Manzoli, Marais, Marais, Marais, Martelli, Martelli, Martin, Mathas, Matthias, May, McCubrey, McCubrey, McCubrey, McCubrey, McCubrey, McCubrey, McCubrey, McCubrey, McCubrey, McCubrey, McCubrey, McGraw, Menard, Menendez, Menendez, Menendez, Menendez, Menendez, Menendez, Menendez, Mercurio, Mijatovic, Milde-Langosch, Milella, Miller, Mills, Mischel, Monden, Montalto, Montminy, Mor, Mori, Morris, Morrison, Morrison, Morrison, Morrison, Mueckler, Muller, Nagarkatti, Nagasue, Narita, Nawrocki, Neckers, Neckers, Neviani, Newton, Newton, Nickels, Nikiforov, Nuñez, O'Regan, Odero, Ohnishi, Ohnishi, Pan, Pandolfi, Pandolfi, Pani, Pani, Parangi, Park, Parry, Parsons, Payne, Peeper, Perkins, Perkins, Phillips, Pinchera, Polk, Pollak, Porter, Pospelov, Prywes, Pujana, Punt, Qian, Raffeld, Rao, Rapp, Rauen, Rocha, Rohrschneider, Rollins, Romanyukha, Rongo, Rosen, Rudel, Ruderman, Ryan, Sabatini, Sabatini, Sahin, Sanchez-Garcia, Sanchez-Puelles, Sanders, Sasaki, Sawyers, Schork, Schug, Scott, Scott, Sellers, Serrano, Settleman, Shapiro, Shaposhnikov, Shaw, Shrikant, Shtivelman, Simon, Simon, Simone, Sobue, Sonenberg, Sonenberg, Sotgia, Steelman, Steiger, Stephens, Stiles, Stoeltzing, Stokoe, Su, Tai, Tai, Tamanoi, Tamburini, Testa, Testa, Testa, Testa, Thor, Thorgeirsson, Timchenko, Treisman, Treisman, Tsou, Tsuda, Tucker-Kellog, Tulchinsky, Tzivion, Valerie, Velculescu, Viollet, Vitale, Vogt, Vogt, Vollrath, von Zglinicki, Wadhwa, Wadhwa, Wang, Weber, Weiss, Wendel, Wesierska-Gadek, White, Wicha, Wilkinson, Wong, Woodgett, Woods, Xu, Yan, Yang, Zacksenhaus, Zamoyska, Zhang, Zhao, Zheng, Zheng, Zhu, Zimmer +409 morecore +3 more sourcesPS1175 DETECTING BCR‐ABL AND SCORING MR: RESULTS FROM A CE‐IVD KIT RUN ON NON‐IVD PCR INSTRUMENTS: A COMPARISON WITH DATA FROM A EUTOS VALIDATED LAB.
HemaSphere, Volume 3, Issue S1, Page 534-535, June 2019., 2019 Background:
Detection of the BCR‐ABL1 fusion transcript in CML patients using RT‐qPCR allows sensitive monitoring of disease levels (minimal residual disease, MRD), which is important for determining prognosis and making treatment decisions. To interpret MRD results correctly in respect to data from clinical trials, it is necessary to report data as IS,J. Petersen, G.W. Novotnywiley +1 more sourcePB1953 QUALITY OF LIFE AND SYMPTOM BURDEN WITH FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
HemaSphere, Volume 3, Issue S1, Page 887-888, June 2019., 2019 Background:
With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age‐ and sex‐matched healthy population. Nevertheless, patients receiving TKIs report chronic adverse events, some of which may be associated with severe symptoms including fatigue, edema, muscle ...T. Toptas, H. Bostan, K. Kut, F. Pepedil Tanrikulu, F. Yilmaz, I. Atagunduz, T. Tuglular +6 morewiley +1 more source
